Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Accounts Payables (2016 - 2025)

Sonoma Pharmaceuticals has reported Accounts Payables over the past 15 years, most recently at $2.1 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 10.18% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, up 10.18%, while the annual FY2025 figure was $2.2 million, 266.39% up from the prior year.
  • Accounts Payables for Q4 2025 was $2.1 million at Sonoma Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $2.3 million in Q2 2023 and troughed at $607000.0 in Q1 2024.
  • A 5-year average of $1.5 million and a median of $1.6 million in 2025 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: tumbled 70.82% in 2021 and later surged 266.39% in 2025.
  • Year by year, Accounts Payables stood at $1.3 million in 2021, then skyrocketed by 70.36% to $2.2 million in 2022, then plummeted by 60.75% to $864000.0 in 2023, then soared by 121.76% to $1.9 million in 2024, then rose by 10.18% to $2.1 million in 2025.
  • Business Quant data shows Accounts Payables for SNOA at $2.1 million in Q4 2025, $1.4 million in Q3 2025, and $1.8 million in Q2 2025.